#	Pagina
attuale pagina	/open-h2020/projects/200823/index.html

Opendata, web and dolomites

PRECIOUS SIGNED

Scaling-up biodegradable nanomedicines for multimodal for multimodal precision cancer immunotherapy

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

PRECIOUS project word cloud

Explore the words cloud of the PRECIOUS project. It provides you a very rough idea of what is the project "PRECIOUS" about.

systemically nanoparticles containing ovarian toxicity track injection tackle reverse shuts bottlenecks antigens formed nanomedicines marketing compounds slowly cancer nanotechnology clinical eagerly relevance gmp leadership microenvironment immunotherapy vigorous immunomodulator renowned immunotherapies prostate manufacturing million evoke immunity precious nanovaccine tumour technologies induce immunosuppression awaited multimodal ket medicines reactivates platform notably scaling release suppression precision excellent activators time hurdle clinic record initiate translation academic biodegradable industrial trial vaccination perform types nanoparticle anti vaccines patients toxic efficacy reverses safe immune disappointing

Project "PRECIOUS" data sheet

The following table provides information about the project.

Coordinator	STICHTING KATHOLIEKE UNIVERSITEIT Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ website: www.radboudumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.precious-h2020.eu
Total cost	8˙291˙217 €
EC max contribution	8˙291˙217 € (100%)
Programme	1. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
Code Call	H2020-NMP-2015-two-stage
Funding Scheme	RIA
Starting year	2016
Duration (year-month-day)	from 2016-05-01 to 2021-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	STICHTING KATHOLIEKE UNIVERSITEIT STICHTING KATHOLIEKE UNIVERSITEIT Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ website: www.radboudumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (NIJMEGEN)	coordinator	1˙802˙005.00
2	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	participant	984˙650.00
3	ITEOS THERAPEUTICS ITEOS THERAPEUTICS Organization address address: RUE DES FRERES WRIGHT 29 city: GOSSELIES postcode: 6041 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (GOSSELIES)	participant	952˙222.00
4	EVONIK NUTRITION & CARE GMBH EVONIK NUTRITION & CARE GMBH Organization address address: RELLINGHAUSER STRASSE 1 11 city: ESSEN postcode: 45128 website: www.evonik.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (ESSEN)	participant	838˙549.00
5	UNIVERSITAT KONSTANZ UNIVERSITAT KONSTANZ Organization address address: UNIVERSITATSSTRASSE 10 city: KONSTANZ postcode: 78464 website: www.uni-konstanz.de/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (KONSTANZ)	participant	828˙126.00
6	SPECIALIZED MEDICAL SERVICES-ONCOLOGY BV SPECIALIZED MEDICAL SERVICES-ONCOLOGY BV Organization address address: WALAARDT SACRESTRAAT 401 city: SCHIPHOL postcode: 1117 BM website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (SCHIPHOL)	participant	722˙689.00
7	FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI Organization address address: Via Venezian 1 city: Milan postcode: 20133 website: www.istitutotumori.mi.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (Milan)	participant	693˙206.00
8	ONCOARENDI THERAPEUTICS SPOLKA AKCYJNA ONCOARENDI THERAPEUTICS SPOLKA AKCYJNA Organization address address: UK ZWIRKI I WIGURY 101 city: WARSZAWA postcode: 02 089 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PL (WARSZAWA)	participant	617˙854.00
9	USTAV MAKROMOLEKULARNI CHEMIE AV CRVVI USTAV MAKROMOLEKULARNI CHEMIE AV CRVVI Organization address address: HEYROVSKY SQ 2 city: PRAHA 6 postcode: 162 06 website: http://www.imc.cas.cz contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CZ (PRAHA 6)	participant	464˙238.00
10	IOX THERAPEUTICS LIMITED IOX THERAPEUTICS LIMITED Organization address address: 200 STRAND city: LONDON postcode: WC2R 1DJ website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	242˙295.00
11	TTOPSTART BV TTOPSTART BV Organization address address: EUCLIDESLAAN 1 city: UTRECHT postcode: 3584 BL website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (UTRECHT)	participant	145˙377.00

Map

Project objective

PRECIOUS aims at scaling-up biodegradable nanomedicines for multimodal precision cancer immunotherapy. With 3.5 million cancer patients in Europe every year, new cancer medicines are eagerly awaited, notably for prostate and ovarian cancer. Systemically applied new immunotherapies are promising, but their toxicity is a hurdle. Vaccination against cancer is safe but rather the efficacy can be disappointing, i.e. the microenvironment shuts down anti-tumour immunity.

PRECIOUS will tackle 2 bottlenecks: 1. Production of non toxic multimodal nanomedicines, which induce vigorous immune responses, and at the same time reverse immunosuppression 2. Large scale GMP production of nanomedicines, and initiate a multimodal immunotherapy Phase I trial.

We want to solve these bottlenecks by: Objective 1: Two types of GMP biodegradable nanoparticles: 1) a nanovaccine, containing tumour antigens and immune activators, and 2) a nanoparticle composed of compounds, which reverses the suppression and reactivates immunity in the tumour. Objective 2: Clinical Phase I trial to show efficacy. Nanomedicines will be used by 1) injection of vaccines to evoke immune responses and 2) injection of nanoparticles in the tumour microenvironment, which slowly release compounds that reverse suppression.

To achieve this, a platform is formed with 6 leading industrial partners to produce large scale GMP nanomedicines and an excellent immunomodulator track record, together with 5 renowned academic partners to perform clinical studies. Relevance to call: Large scale GMP production, industrial leadership, nanotechnology and advanced manufacturing KET technologies, translation to the clinic, marketing development.

Publications

List of publications.
year	authors and title	journal	last update
2018	Giuseppe Lo Russo, Massimo Moro, Michele Sommariva, Valeria Cancila, Mattia Boeri, Giovanni Centonze, Simona Ferro, Monica Ganzinelli, Patrizia Gasparini, Veronica Huber, Massimo Milione, Luca Porcu, Claudia Proto, Giancarlo Pruneri, Diego Signorelli, Sabina Sangaletti, Lucia Sfondrini, Chiara Storti, Elena Tassi, Alberto Bardelli, Silvia Marsoni, Valter Torri, Claudio Tripodo, Mario Paolo Colombo, Andrea Anichini, Licia Rivoltini, Andrea Balsari, Gabriella Sozzi, Marina Chiara Garassino Antibodyâ€“Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Nonâ€“small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade published pages: , ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-18-1390	Clinical Cancer Research	2020-02-25
2018	Veronica Huber, Viviana Vallacchi, Viktor Fleming, Xiaoying Hu, Agata Cova, Matteo Dugo, Eriomina Shahaj, Roberta Sulsenti, Elisabetta Vergani, Paola Filipazzi, Angela De Laurentiis, Luca Lalli, Lorenza Di Guardo, Roberto Patuzzo, Barbara Vergani, Elena Casiraghi, Mara Cossa, Ambra Gualeni, Valentina Bollati, Flavio Arienti, Filippo De Braud, Luigi Mariani, Antonello Villa, Peter Altevogt, Viktor Umansky, Monica Rodolfo, Licia Rivoltini Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma published pages: 5505-5516, ISSN: 0021-9738, DOI: 10.1172/jci98060	Journal of Clinical Investigation 128/12	2020-02-25
2016	Valerie L. Herrmann, Daniel E. Wieland, Daniel F. Legler, Valentin Wittmann, Marcus Groettrup *The STEAP1 262-270 peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A0201 transgenic mice-A new approach to immunotherapy against prostate carcinoma** published pages: 456-468, ISSN: 0270-4137, DOI: 10.1002/pros.23136	The Prostate 76/5	2020-02-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRECIOUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PRECIOUS" are provided by the European Opendata Portal: CORDIS opendata.